Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses

[1]  Pauline M Rudd,et al.  Glycans as cancer biomarkers. , 2012, Biochimica et biophysica acta.

[2]  W. Ju,et al.  Genomic biomarkers for chronic kidney disease. , 2012, Translational research : the journal of laboratory and clinical medicine.

[3]  C. Lebrilla,et al.  Annotation of a serum N-glycan library for rapid identification of structures. , 2012, Journal of proteome research.

[4]  Karen Kelly,et al.  N-Glycan profiling of dried blood spots. , 2012, Analytical chemistry.

[5]  S. Rea,et al.  Applications of mass spectrometry to metabolomics and metabonomics: detection of biomarkers of aging and of age-related diseases. , 2012, Mass spectrometry reviews.

[6]  Kwon-Sik Park,et al.  Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. , 2011, Cancer cell.

[7]  C. Lebrilla,et al.  Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers. , 2011, The Analyst.

[8]  Karl Mechtler,et al.  Quality control in LC‐MS/MS , 2011, Proteomics.

[9]  Scott R. Kronewitter,et al.  Human serum processing and analysis methods for rapid and reproducible N-glycan mass profiling. , 2010, Journal of proteome research.

[10]  Yehia Mechref,et al.  Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery. , 2010, Analytical chemistry.

[11]  Scott R. Kronewitter,et al.  The development of retrosynthetic glycan libraries to profile and classify the human serum N‐linked glycome , 2009, Proteomics.

[12]  Predictive Biomarkers in the Development of Oncology Drugs: A Therapeutic Industry Perspective , 2009, Clinical pharmacology and therapeutics.

[13]  K. Killeen,et al.  Profile of native N‐linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time‐of‐flight mass spectrometry , 2009, Proteomics.

[14]  Angela Mariotto,et al.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.

[15]  André M Deelder,et al.  Oligosaccharide analysis by graphitized carbon liquid chromatography–mass spectrometry , 2009, Analytical and bioanalytical chemistry.

[16]  Carlito B. Lebrilla,et al.  The prospects of glycan biomarkers for the diagnosis of diseases. , 2009, Molecular bioSystems.

[17]  Marie-Christine W. Gast,et al.  Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS) , 2009, Clinical chemistry and laboratory medicine.

[18]  Masato Kato,et al.  Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy. , 2008, Hepato-gastroenterology.

[19]  Christos Hatzis,et al.  Commercialized multigene predictors of clinical outcome for breast cancer. , 2008, The oncologist.

[20]  N. Packer,et al.  A general approach to desalting oligosaccharides released from glycoproteins , 1998, Glycoconjugate Journal.